At a staff town hall meeting, FDA officials tried to quell concerns about a controversial new program to fast-track certain drugs.[1] A program called the Commissioner's National Priority Voucher (CNPV) was introduced in June 2025 and allows the review process to be shortened from 10-12 months to 1-2 months for drugs meeting national priorities.[1][3] Priorities include addressing public health, innovative treatments, unmet medical needs, domestic production, and increasing the availability and affordability of medicines.[1][3] So far, 18 products have received vouchers, including the recent LDL cholesterol-lowering Enlicitide decanoate and Sacituzumab Tirumotecan.[1] The FDA approved the first drug through the program, but delayed reviews of two drugs due to safety and efficacy concerns.[4][5][7][8] The program involves increased communication with reviewers and may lead to accelerated approval.[3] One of the criteria is increasing affordability, which has led to agreements to reduce the prices of other drugs.[2]